SCHEMBL5659664

SCHEMBL5659664

COC(=O)c1cc(OC)c(OC)c2oc(C(=O)c3ccccc3)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ KDM4E B2RXH2 6/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ ATM Q13315 1/20 0.45
▸ MAPT P10636 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ PDE4A P27815 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659646 0.93 SMN1; SMN2 (0.47) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL5658511 0.89 MAPT (0.54) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL5668947 0.88 SMN1; SMN2 (0.45) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL6837653 0.85 SMN1; SMN2 (0.60) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL5669321 0.85 KDM4E (0.49) KDM4EHSD17B10MAPK1MAPTHTT
SCHEMBL5657720 0.81 KDM4E (0.46) SMN1; SMN2KDM4EHSD17B10MAPK1HTT
SCHEMBL5661034 0.81 ACHE (0.55) KDM4EHSD17B10MAPK1MAPTHTT
SCHEMBL5655755 0.79 KDM4E (0.46) KMT2AMEN1SMN1; SMN2KDM4EHSD17B10
SCHEMBL5657180 0.79 KDM4E (0.46) KMT2AMEN1KDM4EHSD17B10MAPK1
SCHEMBL5655693 0.78 KDM4E (0.45) KDM4EHSD17B10MAPK1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030130-B2 Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2006-04-18 — — US disclosed
EP-1307445-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2005-12-21 — — EP disclosed
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents EVOLVA SA (CH) 2004-02-19 — — US disclosed
EP-1307445-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Arpida AG, (CH) 2003-05-07 — — EP disclosed
WO-2002010156-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 — — WO disclosed
WO-2002010157-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents SBDS, BPTF, DCXR KMT2A 3563/4885MEN1 4413/4885NPC1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback